554 related articles for article (PubMed ID: 31090219)
1. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK
Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219
[TBL] [Abstract][Full Text] [Related]
2. Disruption of RBMS3 suppresses PD-L1 and enhances antitumor immune activities and therapeutic effects of auranofin against triple-negative breast cancer.
Zhou Y; Liang Z; Xia Y; Li S; Liang J; Hu Z; Tang C; Zhao Q; Gong Q; Ouyang Y
Chem Biol Interact; 2023 Jan; 369():110260. PubMed ID: 36414028
[TBL] [Abstract][Full Text] [Related]
3. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
4. Methionine restriction exposes a targetable redox vulnerability of triple-negative breast cancer cells by inducing thioredoxin reductase.
Malin D; Lee Y; Chepikova O; Strekalova E; Carlson A; Cryns VL
Breast Cancer Res Treat; 2021 Dec; 190(3):373-387. PubMed ID: 34553295
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
[TBL] [Abstract][Full Text] [Related]
6. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
7. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
Juliá EP; Amante A; Pampena MB; Mordoh J; Levy EM
Front Immunol; 2018; 9():2140. PubMed ID: 30294328
[TBL] [Abstract][Full Text] [Related]
8. Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species.
Wang H; Bouzakoura S; de Mey S; Jiang H; Law K; Dufait I; Corbet C; Verovski V; Gevaert T; Feron O; Van den Berge D; Storme G; De Ridder M
Oncotarget; 2017 May; 8(22):35728-35742. PubMed ID: 28415723
[TBL] [Abstract][Full Text] [Related]
9. MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.
Maeda T; Hiraki M; Jin C; Rajabi H; Tagde A; Alam M; Bouillez A; Hu X; Suzuki Y; Miyo M; Hata T; Hinohara K; Kufe D
Cancer Res; 2018 Jan; 78(1):205-215. PubMed ID: 29263152
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
Li X; Tang L; Chen Q; Cheng X; Liu Y; Wang C; Zhu C; Xu K; Gao F; Huang J; Wang R; Guan X
Chin Med J (Engl); 2022 Oct; 135(20):2436-2445. PubMed ID: 36583862
[TBL] [Abstract][Full Text] [Related]
11. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
Loi S; Dushyanthen S; Beavis PA; Salgado R; Denkert C; Savas P; Combs S; Rimm DL; Giltnane JM; Estrada MV; Sánchez V; Sanders ME; Cook RS; Pilkinton MA; Mallal SA; Wang K; Miller VA; Stephens PJ; Yelensky R; Doimi FD; Gómez H; Ryzhov SV; Darcy PK; Arteaga CL; Balko JM
Clin Cancer Res; 2016 Mar; 22(6):1499-509. PubMed ID: 26515496
[TBL] [Abstract][Full Text] [Related]
12. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
14. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
15. RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
Tentler JJ; Lang J; Capasso A; Kim DJ; Benaim E; Lee YB; Eisen A; Bagby SM; Hartman SJ; Yacob BW; Gittleman B; Pitts TM; Pelanda R; Eckhardt SG; Diamond JR
BMC Cancer; 2020 Nov; 20(1):1063. PubMed ID: 33148223
[TBL] [Abstract][Full Text] [Related]
16. A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer.
Wu X; Li F; Li Y; Yu Y; Liang C; Zhang B; Zhao C; Lu A; Zhang G
Med Sci Monit; 2020 Jun; 26():e925583. PubMed ID: 32574155
[TBL] [Abstract][Full Text] [Related]
17. Alantolactone promotes ER stress-mediated apoptosis by inhibition of TrxR1 in triple-negative breast cancer cell lines and in a mouse model.
Yin C; Dai X; Huang X; Zhu W; Chen X; Zhou Q; Wang C; Zhao C; Zou P; Liang G; Rajamanickam V; Wang O; Zhang X; Cui R
J Cell Mol Med; 2019 Mar; 23(3):2194-2206. PubMed ID: 30609207
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.
Reguera-Nuñez E; Xu P; Chow A; Man S; Hilberg F; Kerbel RS
J Exp Clin Cancer Res; 2019 Jan; 38(1):16. PubMed ID: 30635009
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic targeting of thioredoxin reductase 1 causes ferroptosis while potentiating anti-PD-1 efficacy in head and neck cancer.
Hsieh MS; Ling HH; Setiawan SA; Hardianti MS; Fong IH; Yeh CT; Chen JH
Chem Biol Interact; 2024 May; 395():111004. PubMed ID: 38636790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]